Skip to content

Pan-Canadian Lung Cancer Observational Study (PALEOS)

Lung Cancer

This study is a multicenter, ambispective observational study that will collect data focusing on patients with lung cancers in Canada. The study will begin with ALK, EGFR, ROS1, ERBB2 (HER2), exon 20 EGFR mutation, MET and BRAF patients, with the goal of expanding into other rare molecular alterations within year 2

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Adults aged 18 years or older confirmed having lung cancer diagnosis since 2006.
* Canadian residents having lung cancer diagnosis with follow-up for cancer care occurring or planned to occur in Canada at the time of enrolment.

Exclusion Criteria:

- Inability to provide informed consent.

Lieu de l'étude

Milena (Lynn) Vicente
Milena (Lynn) Vicente
Brampton, Ontario
Canada

Contactez l'équipe d'étude

Backup Contact

Shawna Noy

[email protected]
905 494 2120
Primary Contact

Lynn Vicente

[email protected]
4164362556
Étude parrainée par
William Osler Health System
Participants recherchés
Plus d'informations
ID de l'étude: NCT04706754